J. M. Carreno

This study compares mucosal antibody responses in individuals who received mRNA booster vaccinations or experienced breakthrough infections, finding that breakthrough infections induce stronger saliva sIgA responses than boosters.

This study investigates whether immunity to seasonal coronavirus spike proteins protects against SARS-CoV-2 in mice and affects mRNA vaccine efficacy, finding no increased protection but no detrimental effect on vaccination.

This study shows that RBD antibodies contribute more to SARS-CoV-2 neutralization when target cells have high ACE2 expression, highlighting ACE2 levels as a critical experimental factor.

The paper tests a trivalent NDV-HXP-S vaccine against SARS-CoV-2 variants in mice, showing increased protection and cross-neutralizing antibodies against Omicron.

This paper identifies a broadly neutralizing antibody, STI-9167, effective against SARS-CoV-2 variants including Omicron and Omicron + R346K, and describes its development for clinical trials.

This study evaluates the protective efficacy of mRNA vaccines against SARS-CoV-2 variants in mice, showing that low-dose vaccines lead to breakthrough infections with Delta variant.

The paper structures a germline-like antibody in complex with SARS-CoV-2 spike NTD, revealing a neutralizing epitope and its conservation across variants.

This study identifies novel epitopes of human monoclonal antibodies targeting the influenza virus N1 neuraminidase and characterizes escape mutations and their impact on viral fitness.

This study generates and characterizes monoclonal antibodies against the N6 neuraminidase subtype of influenza viruses, showing broad reactivity and antiviral activity, but limited inhibition of H5N6 NA.